The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy

Journal of Internal Medicine

Volumn 245, Issue 5, 1999, Pages 435-443

  Jansson, Kjell ^a   Dahlstrom U ^a   Karlberg, B E ^a   Karlsson, E ^a   Nylander, E ^a   Nyquist, O ^b   Karlberg, K E ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACE inhibitor; Captopril; Metoprolol; Neurohormonal function; Non ischaemic cardiomyopathy; Renin angiotensin system

Indexed keywords

CAPTOPRIL; METOPROLOL;

ADULT; ALDOSTERONE URINE LEVEL; ANGIOTENSIN BLOOD LEVEL; ARTICLE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG TOLERABILITY; EXERCISE; FEMALE; HEART DILATATION; HEART VENTRICLE PERFORMANCE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REST;

EID: 0032947426     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00458.x     Document Type: Article

References (47)

1. Packer M. Survival in patients with chronic heart failure and its potential modification by drug therapy. In: Cohn J, ed. Drug Treatment of Heart Failure, 2nd edn. Secaunus N. ATC International, 1988;273-88.
2. Nicholls MG. The natriuretic peptides in heart failure. J Intern Med 1994; 235: 515-26.
3. DeBold A, Borenstein H, Veress A, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89.
4. Raine A, Erne P, Bürgisser E et al. Atrial peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986; 315: 533-37.
5. Fitzpatrick MA, Nicholls MG, Ikram H, Espiner EA. Stability and interrelationships of hormones, haemodynamic and electrolyte levels in heart failure in man. Clin Exp Pharmacol Physiol 1985; 12: 145-54.
6. Fyhrquist F, Tikkanen I. Atrial natriuretic peptide in congestive heart failure. Am J Cardiol 1988; 62: 20-24A.
7. Kirlin P, Grekin R, Das S, Ballor E, Johnson T, Pitt B. Neurohormonal activation during exercise in congestive heart failure. Am J Med 1986; 81: 623-29.
8. Nishikimi T, Kohno M, Matsura T et al. Effect of exercise on circulating atrial natriuretic polypeptide in valvular heart disease. Am J Cardiol 1986; 58: 1119-20.
9. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. for the Consensus Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-36.
10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302.
11. Waagstein F, Hjalmarson Ä, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-36.
12. Engelmeier R, O'Connell J, Walsh R, Rad N, Scanlon P, Gunnar R. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985; 72: 536-46.
13. Anderson J, Lutz JR, Gilbert E et al. A randomized trial of low- dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 471-75.
14. Swedberg K, Hjalmarson Ä, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980; 44: 117-33.
15. Waagstein F, Bristow M, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-46.
16. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med 1996; 334: 1349-55.
17. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta-blockade in congestive cardiomyopathy. Lancet 1981; 79: 490-93.
18. Currie PF, Kelly MJ, McKenzie A et al. Oral beta-adrenergic blockade with metoprolol in chronic severe congestive cardiomyopathy. J Am Coll Cardiol 1984; 3: 203-209.
19. WHO/ISFC Task Force on the Definition and Classification of Cardiomyopathies. Report. Br Heart J 1980; 44: 672-73.
20. Sahn J, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-83.
21. Henry W, Gardin J, Ware J. Echocardiographic measurements in normal subjects from infancy to old age. Circulation 1980; 62: 1054-61.
22. Nordesjö L, Landelius J. Clinical evaluation of physical work capacity. Scand J Clin Lab Invest 1975; 35(Suppl. 143):
23. Fyhrquist F, Soveri P, Puutula L, Stenman U. Radioimmunoassay of plasma renin activity. Clin Chem 1976; 22: 250-56.
24. Kappelgaard A, Damkjaer-Nielsen M, Giese J. Measurement of angiotensin II in human plasma. Technical modifications and practical experience. Clinica Chimica Acta 1976; 67: 299-306.
25. McKenzie J, Clements JM. Simplified radioimmunoassay for serum aldosterone utilizing increased antibody specificity. J Clin Endocrinol 1974; 38: 622-27.
26. Brown R, Swander A, McKenzie JM. Urine aldosterone radioimmunoassay: validation of a method without chromatography. J Clin Endocrinol 1976; 42: 894-900.
27. Capper S, Smith S, Spensley C, Whateley J. Specificities compared for a radioreceptor assay and a radioimmunoassay of atrial natriuretic peptide. Clin Chem 1990; 36: 656-58.
28. Jansson K, Karlberg KE, Nylander E, Karlsson E, Nyquist O, Dahlström U. More favourable haemodynamic effects of metoprolol than of captopril in patients with dilated cardiomyopathy. Eur Heart J 1997; 18: 1115-21.
29. Francis G, Benedict C, Johnstone D et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990; 82: 1724-29.
30. Anand I, Kalra G, Harris P et al. Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience 1991; 2: 273-78.
31. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464-69.
32. Berglund H, Jensen-Urstad M, Theodorsson E, Bevegärd S. Plasma levels of atrial natriuretic peptide at rest and during exercise in heart failure - influence of cardiac rhythm and haemodynamics. Clin Physiol 1991; 11: 183-96.
33. Richards AM, Tonolo G, Tree M et al. Atrial natriuretic peptides and renin release. Am J Med 1988; 84: 112-18.
34. Eichhorn E, McGhie A, Bedotto J et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991; 67: 67-73.
35. Eichhorn E. The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am J Med 1992; 5: 527-38.
36. Lanzillo J, Dasarathy Y, Stevens J, Fanburg B. Conversion of angiotensin I to angiotensin II by a latent endothelial cell peptidyl dipeptidase that is not angiotensin converting enzyme. Biochem Biophys Res Commun 1986; 2: 770-76.
37. Changaris D, Miller J, Levy R. Angiotensin II generated by a human renal carboxypeptidase. Biochem Biophys Res Commun 1986; 2: 573-79.
38. Urata H, Akio K, Misono K, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in human heart. J Biol Chem 1990; 36: 22 348-57.
39. Crozier I, Nicholls MG, Ikram H, Espiner EA, Yandle TG. Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition. Clin Exper Pharmacol Physiol 1989; 16: 417-24.
40. Webster M, Sharpe D, Coxon R et al. Effect of reducing atrial pressure on atrial natriuretic factor and vasoactive hormones in congestive heart failure secondary to ischemic and nonischemic dilated cardiomyopathy. Am J Cardiol 1989; 63: 217-21.
41. Wade C, Claybaugh J. Plasma renin activity, vasopressin concentration and urinary excretory responses to exercise in men. J Appl Physiol 1980; 49: 930-36.
42. Convertino V, Keil L, Greenleaf J. Plasma volume, renin and vasopressin responses to graded exercise after training. J Appl Physiol 1983; 54: 508-14.
43. Tanaka H, Shindo M, Gutkowska J et al. Effect of acute exercise on plasma immunoreactive atrial natriuretic factor (IR-ANF). Life Science 1986; 39: 1685-93.
44. Hodsman G, Phillips P, Ogawa K, Johnston CI. Atrial natriuretic factor in normal man: effects of tilt, posture, exercise, and haemorrhage. J Hypertens 1986; 6 (Suppl. 4): S503-505.
45. Brennan LA, Malvin RL, Jochim KE, Roberts DE. Influence of right and left atrial receptors on plasma concentrations of ADH and renin. Am J Physiol 1971; 221: 273-78.
46. Kohno M, Yasunari K, Yokokawa K et al. Plasma brain natriuretic peptide during ergometric exercise in hypertensive patients with left ventricular hypertrophy. Metabolism 1996; 45: 1326-29.
47. Aldigier J, Huang H, Dalmay F et al. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993; 21: 289-95.